| Patient | John Henry Holliday |
|---|---|
| Date of birth | 2004-08-14 |
| Identifiers | MRN HR-NI007-SYN; SSN (made up) 000-07-8153 |
| Document date | 2026-09-22 |
| Author | Martin Beaumont, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Adult preventive visit; no new complaints. [S]
Mr. Holliday returns for his adult preventive visit five weeks after his end-of-treatment review. He finished all 182 doses of tuberculosis treatment and has had no cough, fever, night sweats, or weight loss since. He is working full days at the dental office. He has kept to one or two drinks once a week, with no evening of heavy drinking since the spring, and he still sees his substance-use counselor once a month. He completed the health risk assessment before the visit. [S]
| Element | Detail |
|---|---|
| Visit | Adult preventive visit, age 22 |
| Active conditions | Pulmonary tuberculosis, treatment completed; alcohol use disorder, mild, improving |
| Medicines | None since tuberculosis treatment ended |
| Functional status | Independent; working full days |
Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good, much better than at the start of the year |
| Psychosocial | Shares an apartment with a roommate; friends nearby; work going well |
| Behavioral | One or two drinks once a week (AUDIT-C 3); no tobacco or other drugs; plays cards on weekends, home by midnight |
| Nutrition | Three meals a day; weight up 8 kg since diagnosis |
| Physical activity | Walks to work; no other exercise |
| Activities of daily living | Independent in all |
| Occupational | Dentist; wears a surgical mask and eye protection with every patient and an N95 respirator for aerosol-generating procedures in patients with suspected tuberculosis |
| Sleep | About seven hours a night |
| Safety | Wears a seat belt; no firearms at home; smoke detector working |
| Hearing and vision | No concerns; vision normal at the end of ethambutol |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight up; no fever or night sweats |
| Eyes | Negative | No blurred vision or color change |
| Ears, nose, mouth, and throat | Negative | No sore throat or hoarseness |
| Cardiovascular | Negative | No chest pain or palpitations |
| Respiratory | Negative | No cough, sputum, hemoptysis, or breathlessness |
| Gastrointestinal | Negative | No nausea or abdominal pain |
| Genitourinary | Negative | No urinary symptoms |
| Musculoskeletal | Negative | No joint pain |
| Integumentary | Negative | No rash |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
11 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Isoniazid 300 mg tablet, one tablet daily | 300 mg once daily by video-observed therapy with the health department, seven days a week, for six months | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
| Rifampin 300 mg capsules, two capsules (600 mg) daily | 600 mg once daily on an empty stomach by video-observed therapy with the health department, seven days a week, for six months | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
| Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily | 1500 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase | Oral route | 2026-02-12 to 2026-04-08 | completed | S |
| Ethambutol 400 mg tablets, three tablets (1200 mg) daily | 1200 mg once daily by video-observed therapy with the health department, seven days a week, until susceptibility results return | Oral route | 2026-02-12 to 2026-03-10 | stopped | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-22 | Body height | 178 | cm | S |
| 2026-09-22 | Body weight | 66 | kg | S |
| 2026-09-22 | Body mass index (BMI) [Ratio] | 20.8 | kg/m2 | S |
| 2026-09-22 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-09-22 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-09-22 | Heart rate | 68 | /min | S |
| 2026-09-22 | Respiratory rate | 14 | /min | S |
| 2026-09-22 | Body temperature | 36.6 | Cel | S |
| 2026-09-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-22 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-09-22 | Total score [AUDIT-C] | 3 | {score} | S |
Vital signs recorded on 2026-09-22; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well-appearing; BMI 20.8 |
| Eyes | Conjunctivae normal; no icterus |
| Ears, nose, and throat | Normal |
| Neck | No lymph nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear; no crackles |
| Abdomen | Soft; liver not enlarged |
| Skin | No rash or suspicious lesions |
| Neurological | Normal sensation in the feet |
| Psychiatric | Relaxed and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance | active | confirmed | A15.0 | S — Synthetic modern coding of his documented pulmonary tuberculosis at the time of diagnosis; the bacteriology is synthetic. |
| Alcohol use disorder, mild, with binge drinking | active | confirmed | F10.10 | S — Synthetic modern coding anchored to the documented heavy drinking; the severity and the criteria met are synthetic. |
| Acute viral gastroenteritis during tuberculosis treatment, with a mild aminotransferase rise below the threshold for drug-induced liver injury; resolved | resolved | confirmed | A08.4 | S — Synthetic intercurrent illness chosen to teach the assessment of nausea on isoniazid and rifampin; it does not echo a documented illness. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Influenza vaccine, 2026-2027 | Completed today | Given today; recommended for health-care personnel |
| Hepatitis B vaccine | Completed today | Not immune at diagnosis (surface antigen and surface antibody negative). First of two HepB-CpG doses today; second in one month; surface antibody one to two months after the second dose, as for all health-care personnel |
| COVID-19 vaccine, 2026-2027 | Due | Recommended; he will get it at his pharmacy |
| Measles, mumps, rubella and varicella immunity | Up to date | Two documented doses of each in his childhood record, as required for health-care personnel |
| Tetanus, diphtheria, and pertussis booster | Up to date | Tdap about four years ago |
| HPV vaccine | Up to date | Series completed in adolescence by his report |
| HIV screening | Up to date | Negative at the tuberculosis diagnosis |
| Hepatitis C screening | Up to date | Antibody negative at the tuberculosis diagnosis |
| Tuberculosis screening at work | Not indicated | A skin or blood test stays positive after tuberculosis; a yearly symptom screen replaces it |
| Depression screening | Completed today | PHQ-2 score 0 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C 3, below the risk threshold; counseling continues |
| Tobacco use | Completed today | Never used |
| Blood pressure screening | Completed today | 118/72 mmHg |
| Diabetes screening | Not indicated | BMI 20.8 with no risk factors; HbA1c 5.2 percent at diagnosis |
| Sexual health and STI screening | Completed today | Discussed privately; no screening indicated by his history; condoms discussed |
Immunizations given today: Influenza vaccine, 2026-2027 season; Hepatitis B vaccine (HepB-CpG), dose 1 of 2 [S]
Guideline basis: Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Age (2026); Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP) (2011)
Follow-up: Second hepatitis B dose in one month at a nurse visit, and surface antibody one to two months after it. Next preventive visit in one year. [S]
Brief voluntary discussion, offered because of this year's serious illness. He wants to think about whom to name as his health care agent and was given the state's health care directive form to complete at home. No treatment preferences are recorded. [S]